Plain-English translation of NCT06588413 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a lower dose of works as well as a higher dose when combined with three other standard anti-nausea medications. Patients with multiple myeloma who are receiving high-dose chemotherapy before a stem cell transplant often experience severe nausea and vomiting, and this study aims to find the best dose of this medication to prevent those side effects while minimizing drowsiness.
Chemotherapy-induced nausea and vomiting can be serious and affect quality of life during transplant recovery. Doctors want to find the lowest effective dose of this medication that provides good nausea control without making patients excessively drowsy.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either a 2.5 mg or 5 mg dose of the medication, along with three other standard anti-nausea drugs. You'll take the medication on the day you receive your high-dose chemotherapy and for three days afterward. The study will monitor how well the medication prevents nausea and vomiting, as well as any drowsiness or other side effects you experience.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States